LN:VRP Verona Pharma plc

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.This company has ADRs that trade in the U.S. as the symbol VRNA.

55.00 GBP
As of 10/29/2020

---

Security Information

---

Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  United Kingdom
IPO date:  01/01/1900
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   228,000,304 GBP
Current dividend yield:   0.00%
Sedol: